榴莲视频

Insurance claims data show lower glucocorticoid usage at 1 year

Nipocalimab plus standard of care reduced IgG and was well tolerated

Differences between delandistrogene moxeparvovec and placebo emerge in secondary outcomes

Phase III trial met primary endpoint at 6 months

Topline phase III data show inebilizumab met primary endpoint

Small VA-based study saw promising short-term results with no adverse events

Subcutaneous formulation lowers relapse risk in debilitating autoimmune disorder

Benefits maintained after multiple treatment cycles

44% of treated patients with CIDP showed improvement after switching to riliprubart

Hospitalization dropped threefold, real-world data show

Findings suggest patients with SCLC are not screened for LEMS, despite their association